Press Releases-SINOVAC: Supply Vaccines to Eliminate Human Diseases-page8

2019/07/10

Sinovac Reports Unaudited First Quarter 2019 Financial Results

2019/04/29

Sinovac Reports Unaudited Second Half of 2018 Financial Results and Files 2018 Annual Report on Form 20-F

2019/04/16

Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the JID

Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in The Journal of Infectious DiseasesThe Sinovac-developed sIPV demonstrates

2019/04/13

Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares

2019/03/08

Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares

2019/02/22

Sinovac Determines Trigger Event Occurred Under Rights Agreement

2018/12/19

Sinovac Comments on Antigua and Barbuda Court Decision Denying 1Globe Capital’s Claim; Current Board Was Validly Elected at Annual General Meeting

2018/12/13

Haidian District People’s Court in Beijing Issues Injunction Order Restraining Aihua Pan from Using Business License and Corporate Seal of Sinovac Bei

2018/11/29

Hong Kong High Court Issues Declaratory Orders and Permanent Injunctive Relief in Favor of Sinovac’s Senior Management

2018/11/08

Sinovac Reports Unaudited First Half of 2018 Financial Results

2018/10/22

Sinovac Granted Interim Injunctive Relief Regarding Filings Bearing a Falsified Company Seal and Forged Board Member Signatures

2018/10/17

U.S. District Court in Massachusetts Denies 1Globe’s Motion for Preliminary Injunction to Enjoin Sinovac’s Issuance of Shares

2018/10/16

Sinovac Commences Legal Proceedings to Nullify Filings Bearing a Falsified Company Seal and Forged Board Member Signatures

2018/10/10

Sinovac Comments on Unauthorized Use of Falsified Sinovac Hong Kong’s Company Seal and Subsidiary Board Member Signatures

2018/09/17

DOJ Closes Investigation of Sinovac

BEIJING, Sept. 17, 2018 -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the U.S.

2018/08/20

SEC Concludes Investigation of Sinovac

2018/07/03

Sinovac Raises $86.73 Million Through Private Placement Transaction

2018/06/26

Sinovac Files Motion for Summary Judgment on Rights Agreement in Delaware Chancery Court

2018/06/11

Sinovac Biotech Relaunches Company Website

2018/05/11